Letter: Proposed new derivative of cytosine arabinoside (NSC-63878) to circumvent resistance.
D000812:Anhydrides / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D003597:Cytosine Nucleotides / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D063065:Organophosphonates / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000812:Anhydrides; D000970:Antineoplastic Agents; D003597:Cytosine Nucleotides; D063065:Organophosphonates; D003561:Cytarabine